Clinical Trials Directory

Trials / Completed

CompletedNCT07166458

Kefir Peptides for Bone Fracture Healing

Fuctional Assessment of Kefir Fermented Milk on the Improvement of Osteoporosis Combined With Fracture Patient

Status
Completed
Phase
N/A
Study type
Interventional
Enrollment
30 (actual)
Sponsor
Jen-Chieh Lai · Academic / Other
Sex
All
Age
50 Years
Healthy volunteers
Not accepted

Summary

This study is designed to evaluate the effects of kefir-derived peptides on bone healing in patients with upper limb fractures. Kefir peptides are natural protein fragments that may promote bone formation and reduce inflammation. Participants with recent upper limb fractures will be randomly assigned to receive either kefir peptide supplementation or standard treatment. The main purpose of this study is to determine whether kefir peptides can accelerate bone healing and improve recovery compared to standard care.

Detailed description

This study aims to investigate the efficacy of kefir-derived peptides in enhancing bone healing after upper limb fractures. Kefir peptides are bioactive fragments of milk proteins that have shown potential in stimulating osteoblast differentiation, inhibiting osteoclast activity, and modulating inflammation in preclinical studies. The study is designed as a randomized, controlled clinical trial. Eligible participants with acute upper limb fractures will be randomly assigned to receive either kefir peptide supplementation in addition to standard care, or standard care alone. The primary objective is to evaluate radiographic and clinical healing at 6 months, while secondary outcomes include pain relief, functional recovery, and quality of life measures. This trial seeks to provide clinical evidence supporting kefir peptides as a safe and natural adjunct therapy to accelerate bone repair, potentially reducing recovery time and improving functional outcomes for patients with fractures.

Conditions

Interventions

TypeNameDescription
DIETARY_SUPPLEMENTKefir PeptideOral supplementation with kefir-derived bioactive peptides given daily in addition to standard care.
OTHERStandard Care (in control arm)Standard fracture management including immobilization, pain control, and routine follow-up care.

Timeline

Start date
2020-04-13
Primary completion
2024-07-20
Completion
2025-04-20
First posted
2025-09-10
Last updated
2026-03-24

Locations

1 site across 1 country: Taiwan

Source: ClinicalTrials.gov record NCT07166458. Inclusion in this directory is not an endorsement.